| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5f7b665fb8f15d0e2b0911539d39f8a2 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-08 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D237-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D295-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-08 |
| filingDate |
1996-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_551cf4621b69233889d5e5e8316ef09f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2aaf08326cfd13b11d77ec651f3ae6a2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8dee52e4c4695da5bd416620e52aad5a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_84fdaec60270824d868f07a53096c279 |
| publicationDate |
1997-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-0771798-A1 |
| titleOfInvention |
Novel polymorphs of lesopitron dichlorohydrate and its hydrated forms, preparation methods and compositions containing them |
| abstract |
It comprises the new polymorphs I and II of Lesopitron dihydrochloride, characterized by their infrared spectra and their X-ray diffraction patterns. They are obtained by crystallization of Lesopitron dihydrochloride. It also comprises the forms I-hydrate and II-hydrate, which are obtained from the corresponding polymorphs, which have a water content from 3 to 6% and from 1.5 to 2.5%, respectively. These products are used in human medicine mainly due to their pharmacological activity over the central nervous system. |
| priorityDate |
1995-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |